Progyny Q4 revenue rises 6.7%, beats expectations

Reuters02-27
<a href="https://laohu8.com/S/PGNY">Progyny</a> Q4 revenue rises 6.7%, beats expectations

Overview

  • Women's health solutions firm's Q4 revenue up 6.7%, beating analyst expectations

  • Adjusted EBITDA for Q4 increased 8.2%, beating analyst estimates

  • Company repurchased 6.5 mln shares, returning $160 mln to shareholders

Outlook

  • Progyny projects 2026 revenue between $1.355 bln and $1.405 bln

  • Company expects 2026 net income of $95.4 mln to $106.1 mln

  • Progyny anticipates first-quarter 2026 revenue of $319 mln to $332 mln

Result Drivers

  • FERTILITY SERVICES - Fertility benefit services revenue increased 11% from Q4 2024

  • MARGIN IMPROVEMENT - Gross margin rose to 24.1% due to efficiencies in care management services

Company press release: ID:nGNXbX6bf1

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$318.40 mln

$307.45 mln (10 Analysts)

Q4 EPS

$0.14

Q4 Net Income

$12.49 mln

Q4 Adjusted EBITDA

Beat

$51.39 mln

$48.56 mln (10 Analysts)

Q4 Gross Profit

$76.88 mln

Q4 Pretax Profit

$17.85 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the managed healthcare peer group is "buy"

  • Wall Street's median 12-month price target for Progyny Inc is $30.00, about 40.6% above its February 25 closing price of $21.33

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment